<p>XBiotech Inc.（纳斯达克代码：XBIT - 获取免费报告）在九月份的空头头寸大幅下降。截至九月三十日，空头头寸总计 119,500 股，较九月十五日的 170,900 股下降了 30.1%。根据平均交易量 52,300 股，目前的空头头寸比率为 2.3 天。公司约有 0.6% 的股票被做空。</p>
<h2>分析师评级变动</h2>
<p>另外，Weiss Ratings 在 10 月 8 日星期三的研究报告中重新发布了对 XBiotech 股票的 “卖出（e+）” 评级。一位股票研究分析师对该股票给予了卖出评级，根据 MarketBeat.com 的数据，该股票的共识评级为 “卖出”。</p>
<p><strong>获取我们对 XBiotech 的最新股票分析</strong></p>
<h2>机构资金流入和流出</h2>
<p>对冲基金和其他机构投资者最近调整了对该股票的持有。汇丰控股 PLC 在第一季度购买了价值约 52,000 美元的 XBiotech 新头寸。美国银行在第二季度将其在 XBiotech 的股份增加了 41.5%。美国银行目前拥有 18,208 股该生物制药公司的股票，价值 54,000 美元，此前在上个季度又购买了 5,344 股。XTX Topco Ltd 在第二季度购买了价值约 61,000 美元的 XBiotech 新头寸。法国巴黎银行金融市场在第二季度将其在 XBiotech 的股份增加了 27.1%。法国巴黎银行金融市场目前拥有 20,729 股该生物制药公司的股票，价值 62,000 美元，此前在上个季度又购买了 4,416 股。最后，Jane Street Group LLC 在第二季度购买了价值约 75,000 美元的 XBiotech 新头寸。当前 55.70% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>XBiotech 股票下跌 3.9%</h2>
<p>纳斯达克：XBIT 周四开盘价为 2.49 美元。该股票的 50 日移动平均价格为 2.84 美元，200 日移动平均价格为 2.90 美元。公司的市值为 7592 万美元，市盈率为-2.71，贝塔值为 0.85。XBiotech 的 52 周低点为 2.35 美元，52 周高点为 8.32 美元。</p>
<p>XBiotech（纳斯达克：XBIT - 获取免费报告）最近于 8 月 13 日星期三发布了季度财报。这家生物制药公司报告本季度每股收益（EPS）为（0.06）美元。</p>
<h2>关于 XBiotech</h2>
<p>（获取免费报告）</p>
<p>XBiotech Inc 是一家生物制药公司，发现、开发和商业化用于治疗各种疾病的真正人类单克隆抗体。该公司专注于开发针对炎症和感染性疾病的产品候选管线。它还在开发白细胞介素-1α疗法，以治疗多种医疗状况，如癌症、中风、心脏病发作或关节炎；并介导组织分解、血管生成、血栓形成、虚弱、肌肉萎缩和炎症。</p>
<h2>另请参见</h2>
<ul>
<li>五只我们更看好的股票，胜过 XBiotech</li>
<li>最大的股票亏损者 - 今天最大的百分比下跌者</li>
<li>Archer 最近的一系列胜利标志着新的增长阶段</li>
<li>航空公司股票 - 现在值得购买的顶级航空公司股票</li>
<li>3 只关键股票在基本面改善的情况下推动回购</li>
<li>CD 计算器：定期存款计算器</li>
<li>选择股票的最佳人工智能，按表现排名</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 XBiotech 吗？</h2>
<p>在你考虑 XBiotech 之前，你会想听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 XBiotech 并不在名单上。</p>
<p>虽然 XBiotech 目前在分析师中被评为卖出评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

XBIT

<p>XBiotech Inc.（纳斯达克代码：XBIT）在九月份的空头头寸下降了 30.1%，总空头头寸从 170,900 股降至 119,500 股。这大约占公司股份的 0.6%。根据平均交易量 52,300 股，目前的覆盖天数比率为 2.3 天。分析师对该股票维持 “卖出” 的共识评级，目前价格为 2.49 美元，下降了 3.9%。机构投资者持有该股票的 55.70%，近期有多家对冲基金进行了购买</p>

<p>XBiotech Inc. (NASDAQ:XBIT - Get Free Report) was the target of a large drop in short interest in September. As of September 30th, there was short interest totaling 119,500 shares, a drop of 30.1% from the September 15th total of 170,900 shares. Based on an average trading volume of 52,300 shares, the short-interest ratio is currently 2.3 days. Approximately 0.6% of the company's stock are short sold. Approximately 0.6% of the company's stock are short sold. Based on an average trading volume of 52,300 shares, the short-interest ratio is currently 2.3 days.</p>
<div class="lb-trans"><p>XBiotech Inc.（纳斯达克代码：XBIT - 获取免费报告）在九月份的空头头寸大幅下降。截至九月三十日，空头头寸总计 119,500 股，较九月十五日的 170,900 股下降了 30.1%。根据平均交易量 52,300 股，目前的空头头寸比率为 2.3 天。公司约有 0.6% 的股票被做空。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>Separately, Weiss Ratings reissued a &#34;sell (e+)&#34; rating on shares of XBiotech in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has a consensus rating of &#34;Sell&#34;.</p>
<div class="lb-trans"><p>另外，Weiss Ratings 在 10 月 8 日星期三的研究报告中重新发布了对 XBiotech 股票的 “卖出（e+）” 评级。一位股票研究分析师对该股票给予了卖出评级，根据 MarketBeat.com 的数据，该股票的共识评级为 “卖出”。</p>
</div><p><strong>Get Our Latest Stock Analysis on XBiotech</strong></p>
<div class="lb-trans"><p><strong>获取我们对 XBiotech 的最新股票分析</strong></p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Hedge funds and other institutional investors have recently modified their holdings of the stock. Hsbc Holdings PLC purchased a new position in shares of XBiotech in the 1st quarter valued at approximately $52,000. Bank of America Corp DE grew its stake in shares of XBiotech by 41.5% in the 2nd quarter. Bank of America Corp DE now owns 18,208 shares of the biopharmaceutical company's stock valued at $54,000 after purchasing an additional 5,344 shares during the last quarter. XTX Topco Ltd purchased a new position in shares of XBiotech in the 2nd quarter valued at approximately $61,000. BNP Paribas Financial Markets grew its stake in shares of XBiotech by 27.1% in the 2nd quarter. BNP Paribas Financial Markets now owns 20,729 shares of the biopharmaceutical company's stock valued at $62,000 after purchasing an additional 4,416 shares during the last quarter. Finally, Jane Street Group LLC purchased a new position in shares of XBiotech in the 2nd quarter valued at approximately $75,000. 55.70% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>对冲基金和其他机构投资者最近调整了对该股票的持有。汇丰控股 PLC 在第一季度购买了价值约 52,000 美元的 XBiotech 新头寸。美国银行在第二季度将其在 XBiotech 的股份增加了 41.5%。美国银行目前拥有 18,208 股该生物制药公司的股票，价值 54,000 美元，此前在上个季度又购买了 5,344 股。XTX Topco Ltd 在第二季度购买了价值约 61,000 美元的 XBiotech 新头寸。法国巴黎银行金融市场在第二季度将其在 XBiotech 的股份增加了 27.1%。法国巴黎银行金融市场目前拥有 20,729 股该生物制药公司的股票，价值 62,000 美元，此前在上个季度又购买了 4,416 股。最后，Jane Street Group LLC 在第二季度购买了价值约 75,000 美元的 XBiotech 新头寸。当前 55.70% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>XBiotech Stock Down 3.9%</h2>
<div class="lb-trans"><h2>XBiotech 股票下跌 3.9%</h2>
</div><p>NASDAQ:XBIT opened at $2.49 on Thursday. The stock's 50 day moving average price is $2.84 and its 200 day moving average price is $2.90. The company has a market capitalization of $75.92 million, a PE ratio of -2.71 and a beta of 0.85. XBiotech has a 52-week low of $2.35 and a 52-week high of $8.32.</p>
<div class="lb-trans"><p>纳斯达克：XBIT 周四开盘价为 2.49 美元。该股票的 50 日移动平均价格为 2.84 美元，200 日移动平均价格为 2.90 美元。公司的市值为 7592 万美元，市盈率为-2.71，贝塔值为 0.85。XBiotech 的 52 周低点为 2.35 美元，52 周高点为 8.32 美元。</p>
</div><p>XBiotech (NASDAQ:XBIT - Get Free Report) last released its quarterly earnings results on Wednesday, August 13th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter.</p>
<div class="lb-trans"><p>XBiotech（纳斯达克：XBIT - 获取免费报告）最近于 8 月 13 日星期三发布了季度财报。这家生物制药公司报告本季度每股收益（EPS）为（0.06）美元。</p>
</div><h2>About XBiotech</h2>
<div class="lb-trans"><h2>关于 XBiotech</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>XBiotech Inc, a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation.</p>
<div class="lb-trans"><p>XBiotech Inc 是一家生物制药公司，发现、开发和商业化用于治疗各种疾病的真正人类单克隆抗体。该公司专注于开发针对炎症和感染性疾病的产品候选管线。它还在开发白细胞介素-1α疗法，以治疗多种医疗状况，如癌症、中风、心脏病发作或关节炎；并介导组织分解、血管生成、血栓形成、虚弱、肌肉萎缩和炎症。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另请参见</h2>
</div><ul>
<li>Five stocks we like better than XBiotech</li>
<li>Biggest Stock Losers - Today’s Biggest Percentage Decliners</li>
<li>Archer’s Recent String of Victories Signals a New Phase of Growth</li>
<li>Airline Stocks - Top Airline Stocks to Buy Now</li>
<li>3 Key Stocks Boosting Buybacks Amid Improving Fundamentals</li>
<li>CD Calculator: Certificate of Deposit Calculator</li>
<li>The Best AI for Picking Stocks, Ranked by Performance</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 XBiotech</li>
<li>最大的股票亏损者 - 今天最大的百分比下跌者</li>
<li>Archer 最近的一系列胜利标志着新的增长阶段</li>
<li>航空公司股票 - 现在值得购买的顶级航空公司股票</li>
<li>3 只关键股票在基本面改善的情况下推动回购</li>
<li>CD 计算器：定期存款计算器</li>
<li>选择股票的最佳人工智能，按表现排名</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in XBiotech Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 XBiotech 吗？</h2>
</div><p>Before you consider XBiotech, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 XBiotech 之前，你会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and XBiotech wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 XBiotech 并不在名单上。</p>
</div><p>While XBiotech currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 XBiotech 目前在分析师中被评为卖出评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

XBiotech Inc.（纳斯达克代码：XBIT）的空头头寸减少了 30.1%